This might be bad news. Many here, me included, thought PFE was logical buyer of $ESPR. PFE already owns big stake in ESPR and it owns Lipitor, the best selling statin ever. But maybe both are wrong. 1. This website shows PFE owns 4.8% of ESPR based on a 2015 filing. Today we learned (I think) that Longitude is also shown as an 11% owner of ESPR based on a 2015 filing. But Longitude site says they exited, so is everything from 2015 is wrong? fintel.io/so/us/espr 2. The footer on lipitor.com/ website shows it is now owned by Viatris $VTRS, the PFE spinoff. In November PFE sent its Upjohn unit VTRS. "The Upjohn Business ... includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica, Lipitor, Celebrex and Viagra." seekingalpha.com/filing/522... PFE website shows it still owns Lipitor, but that's probably wrong: pfizer.com/products-list If PFE no longer has Lipitor, why would it want ESPR? Maybe VTRS wants it?